SD

Subankar Debnath

Active Director Designated Partner DIN 09064058
DIN 09064058 First appointment Feb 2021 Primary industry Home Appliances
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Subankar Debnath

Data last updated:

Subankar Debnath is a Designated Partner at Emoleculare Vets Pharma Llp (since 2021). The company operates in Home Appliances.

DIN 09064058
Primary Designation Designated Partner
Industry Home Appliances
First Appointment 24 Feb 2021
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner24 Feb 20212021Active

Board colleagues of Subankar Debnath

NameDINCompanyDesignation
Ashis Kanti Pal09080700Emoleculare Vets Pharma LlpDesignated Partner
Diptanu Saha09080701Emoleculare Vets Pharma LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Emoleculare Vets Pharma Llp
Premium access

Shareholding and investment profile for Subankar Debnath

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Subankar Debnath

Subankar Debnath currently holds 1 directorship: Emoleculare Vets Pharma Llp (Designated Partner, since 24 Feb 2021).

Subankar Debnath was first appointed on 24 Feb 2021 as Designated Partner at Emoleculare Vets Pharma Llp.

The current boards of Subankar Debnath's companies include Ashis Kanti Pal (Emoleculare Vets Pharma Llp), Diptanu Saha (Emoleculare Vets Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available